Calidi Biotherapeutics, a San Diego, CA-based clinical-stage biotechnology company, raised $25M in Series B funding.
The round was led by Jackson Investment Group, who has funded an initial investment of $5M, and participation from Calidi Cure, LLC, a consortium of new and existing investors. The remaining commitment is conditioned upon the consummation of the previously announced business combination between First Light Acquisition Group (NYSEAMERICAN: FLAG) and Calidi.
The company intends to use the funds to continue the advancement of its pipeline including CLD-101, CLD-201, and CLD-202, which utilize a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications.
Led by CEO Allan Camaisa, Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that works on the effective delivery and potentiation of oncolytic viruses for targeted therapy against difficult-to-treat cancers. The company specializes in clinical development of allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the-shelf, cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety.
FinSMEs
26/06/2023